Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Want to cut your energy bills? Here’s how five experts are doing it 
SAN FRANCISCO, May 30, 2017 -- ProLynx LLC today announced that the United States Patent and Trademark Office has issued US Patent 9,649,385 entitled “Hydrogels with Biodegradable Crosslinking”. The patent broadly covers the use of ProLynx’s ß-eliminative linkers to control the in vivo bio-degradation rate of hydrogels used for drug delivery. Previously, patents were issued on the use of these linkers to control release of drugs tethered to these hydrogel carriers.
The recently issued patent is part of a growing intellectual property portfolio that now includes six issued US patents and five pending US applications, along with 11 issued ex-US patents and corresponding international applications. These patents and applications cover ProLynx proprietary linkers and their use in various applications, including soluble and insoluble conjugates generally as well as specific examples of the technology.
"This patent is an important component of ProLynx's intellectual property portfolio since it extends the utility of our beta-eliminative linkers to controlling the in vivo residence times of our hydrogel microsphere drug carriers," said co-founder and President Daniel V. Santi, M.D., Ph.D. "The technology allows us to balance the rates of drug release and carrier degradation such that after the drug is released, the carrier dissipates, dissolves and eliminates."
About ProLynx.
ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found at http://www.prolynxllc.com.
Contact: Usha Arunachalam: [email protected] Eric Schneider: [email protected] 415-552-5306
